COVID-19 Antivirals & Diagnostics Toolbox for Research: Creative Biolabs Does Its Bit

September 15 13:43 2022
After reviewing the existing detection and treatment modalities for SARS-CoV-2, including vaccines, diagnostics, and antivirals, Creative Biolabs actively participates in building the COVID-19 research toolbox to curb emerging viral variants.

New York, USA – September 14, 2022 – Given existing vaccines and therapeutics may become inefficacious with the evolution of SARS-CoV-2 and its variants, a recent study has reviewed current antiviral treatments and vaccines and emphasized the concept of a COVID-19 medicinal toolkit composed of different antiviral treatments. It also discussed some of the contemporary therapeutic approaches currently under development, including using short interference RNA (siRNA) for SARS-CoV-2 treatment to stay in sync with ever-changing SARS-CoV-2 mutations. Creative Biolabs is a recognized service and product provider for antiviral drug discovery, IVD kit development, and vaccine design, and now joins the worldwide effort to develop a COVID-19 toolbox.

“Doing my share of work in creating a COVID-19 therapeutic and detection toolbox for researchers has been one of the most meaningful and challenging tasks at Creative Biolabs. Fortunately, we’ve accumulated much experience from the 2012 MERS epidemic so that we don’t have to start from the ground up this time, especially in supporting their work in antiviral drug discovery, diagnostic immunoassay development, and vaccine development.” Said the leader of the COVID-19 CRO program at Creative Biolabs.

siRNAs for SARS-CoV-2 Antiviral Therapies

siRNA molecules have become attractive therapeutics in that scientists can rapidly synthesize siRNA sequences for an antiviral effect once mutations are detected in the encoded specific COVID-19 genes. Creative Biolabs has designed various siRNAs focusing on diverse regions of the SARS-CoV-2 genome, the leader sequence, transcription-regulating sequence (TRS), 3′-UTR, the coding sequence for the spike protein, and RNA-dependent RNA polymerase (RdRp) to inhibit coronaviruses-induced cell death. To construct a better SARS-CoV-2 antiviral toolbox, researchers can also exploit the siRNA characterization services within this company.

In Vitro Diagnostic (IVD) Immunoassays for SARS-CoV-2 Detection

In addition to novel antivirals and vaccines that should be added to the COVID toolbox, SARS-CoV-2 detection kits are also necessary for the diagnosis of COVID-19 infection. As a leading supplier of recombinant proteins, antibodies, and kits, Creative Biolabs offers premade SARS-CoV-2 detection kits to hospitals, clinics, as well as testing laboratories. Research platforms and raw reagents are also available to assist researchers to develop molecular diagnostic assays for SARS-CoV-2, from the development and validation of molecular diagnostic test systems to the transfer into new ready-to-use kits for IVD purposes.

As the leader of the COVID-19 CRO program at Creative Biolabs puts it: “Everyone in the industry should take a step in building a comprehensive COVID-19 toolbox. Though with unpredictable roadblocks in this process, we at Creative Biolabs will just keep pushing and finally combat COVID-19 together.”


Creative Biolabs ( is a distinguished contract research organization headquartered in New York. Thousands of talented scientists at Creative Biolabs consistently support different basic research in the industry. Ranked among the top life science companies globally, it offers far more products and services than antiviral drug discovery, vaccine design, and immunoassay development against SARS-CoV-2 only.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States